Cartalax research peptide — wholesale supply

For research use only · Not for human consumption · Not for veterinary use. This product is supplied for in-vitro research, analytical method development, and laboratory reference standard use only. Not approved for human or veterinary administration. Buyer is responsible for end-use classification in the destination jurisdiction.

Overview

Cartalax is a synthetic research peptide positioned in the BPC-157 derivative family, with sequence and structural features that distinguish it from the parent BPC-157 pentadecapeptide. The compound is supplied as a research-grade lyophilized powder, intended for in-vitro cell-based assays, regenerative pathway research, and analytical method development. SPK Pharma India supplies Cartalax as a documented, lot-traceable research compound for distributors, contract manufacturers, and academic laboratories. Cartalax is a niche research SKU with limited B2B supply globally, and lead times may be longer than the standard catalogue SKUs.

Specifications

Research context

Cartalax is studied in cell-based research in the regenerative pathway domain, with the BPC-157 derivative backbone providing the structural basis for cell-based assays in defined cell lines. The compound is supplied for research contexts where the derivative form is the variable of interest, in studies that investigate the contribution of specific sequence modifications to the regenerative pathway profile. The full sequence is disclosed on the lot-matched COA and the product specification sheet.

In-vitro cell-based assays, receptor-binding studies in defined cell lines, and analytical method development for LC-MS quantification of the peptide are the typical research applications. SPK Pharma India does not make therapeutic, clinical, diagnostic, or dosing claims for this product. The compound is supplied strictly for in-vitro research, analytical method development, and reference-standard work.

For researchers new to the compound, the standard analytical reference points are the lot-specific CAS number (disclosed on the COA where applicable), the BPC-157 derivative sequence (disclosed on the COA and the spec sheet), the lot-specific molecular weight, the lyophilized powder form, and the documented purity threshold (≥99% HPLC). Cartalax is a niche research SKU and CAS number, and molecular weight can be confirmed against the lot-matched COA.

Packaging and supply

• 5 mg research vial — for method development, cell-based assays, and reference-standard qualification. Standard MOQ: 5 vials.
• 10 mg research vial — for ongoing research programmes with higher per-assay demand. Standard MOQ: 2 vials.
• Bulk pack — on application, for annual supply contracts and recurring orders.

Distributor pricing is available on application. Annual supply contracts with scheduled recurring dispatch are available for repeat buyers. Lead time for niche SKUs may be longer than the standard catalogue — the trade desk will quote a specific lead time on application.

Quality and documentation

Every lot of Cartalax ships with a lot-matched Certificate of Analysis documenting identity (mass spectrometry and amino acid analysis), purity (HPLC), appearance, lot number, and synthesis batch reference. A representative sample of every lot is independently verified by a third-party analytical laboratory before release. MSDS is supplied with every shipment. The COA template, the lot-traceability workflow, and the third-party verification scope are documented on the Quality page.

Storage and handling

• Store at -20°C in the original sealed container.
• Protect from light and moisture.
• Allow the sealed container to reach room temperature before opening, to avoid condensation.
• Reconstitute in sterile, low-endotoxin research-grade water or in a mild buffer at the working concentration required by the assay.
• Do not refreeze once reconstituted; aliquot and store at working concentration.
• Avoid vigorous vortexing; allow gentle dissolution to minimise aggregation.

Shipping

Cartalax is shipped lyophilized in sealed vials within temperature-validated packaging. International lanes are routed through dedicated life-science logistics partners with cold-chain handling. Standard dispatch is within 5 business days of purchase order confirmation; lead time for niche SKUs may be longer. SPK Pharma India ships to the United States, the European Union, the United Kingdom, Canada, MENA, APAC, and LATAM. Full export documentation, including commercial invoice, packing list, certificate of origin, COA, and MSDS, is included with every shipment. Destination-specific documentation is supported on request.

Compliance

This product is supplied for research use only. It is not a drug, not a finished dosage form, and not approved for human or veterinary administration. SPK Pharma India does not make therapeutic, clinical, diagnostic, or dosing claims for this product. The buyer is responsible for end-use classification in the destination jurisdiction and for ensuring that downstream handling is consistent with research-use-only protocols.

Lead form CTA

To request a wholesale quote for Cartalax, contact the trade desk with the subject line "Cartalax wholesale quote" and your company details, expected volume, and destination country. Distributor pricing is available on application. The desk responds within one business day.

Related compounds

• BPC-157 + TB-500 (2-peptide blend) — base co-formulation
• BPC-157 + TB-500 + GHK-Cu (3-peptide blend) — extended 3-peptide blend
• BPC-157 + TB-500 + GHK-Cu + KPV (4-peptide blend) — full 4-peptide research blend
• GHK-Cu — copper tripeptide research compound
• PEG-MGF — pegylated mechano growth factor research peptide